Klingenstein Fields & Co’s GSK GSK Stock Holding History

Klingenstein Fields & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,731	Closed	-$206K	–	198
2026 Q1	$206K	Buy	+3,731	New	+$202K	0.01%	181
2023 Q2	–	Sell	-6,021	Closed	-$214K	–	171
2023 Q1	$214K	Sell	6,021 -899	-13%	-$31.5K	0.01%	161
2022 Q4	$243K	Buy	6,920 +62	+0.9%	+$2.06K	0.01%	160
2022 Q3	$202K	Sell	6,858 -121,712	-95%	-$4.61M	0.01%	170
2022 Q2	$7M	Sell	128,570 -3,284	-2%	-$181K	0.36%	67
2022 Q1	$7.18M	Sell	131,854 -444	-0.3%	-$24.1K	0.31%	72
2021 Q4	$7.29M	Sell	132,298 -1,760	-1%	-$91.6K	0.29%	70
2021 Q3	$6.4M	Sell	134,058 -2,780	-2%	-$140K	0.27%	69
2021 Q2	$6.81M	Sell	136,838 -7,656	-5%	-$368K	0.28%	69
2021 Q1	$6.45M	Sell	144,494 -15,480	-10%	-$703K	0.29%	66
2020 Q4	$7.36M	Sell	159,974 -1,356	-0.8%	-$62.3K	0.33%	65
2020 Q3	$7.59M	Sell	161,330 -13,802	-8%	-$692K	0.38%	67
2020 Q2	$8.93M	Sell	175,132 -2,697	-2%	-$138K	0.49%	64
2020 Q1	$8.42M	Sell	177,829 -3,772	-2%	-$201K	0.55%	62
2019 Q4	$10.7M	Sell	181,601 -2,317	-1%	-$129K	0.54%	62
2019 Q3	$9.81M	Sell	183,918 -291	-0.2%	-$15K	0.52%	63
2019 Q2	$9.21M	Sell	184,209 -1,881	-1%	-$94.4K	0.48%	65
2019 Q1	$9.72M	Sell	186,090 -183,696	-50%	-$9.18M	0.52%	64
2018 Q4	$17.7M	Sell	369,786 -2,880	-0.8%	-$142K	0.75%	46
2018 Q3	$18.7M	Buy	372,666 +357	+0.1%	+$18.1K	0.67%	51
2018 Q2	$18.8M	Sell	372,309 -1,928	-0.5%	-$97.1K	0.72%	50
2018 Q1	$18.3M	Sell	374,237 -756	-0.2%	-$35.2K	0.7%	49
2017 Q4	$16.6M	Sell	374,993 -7,520	-2%	-$347K	0.61%	51
2017 Q3	$19.4M	Sell	382,513 -3,424	-0.9%	-$174K	0.75%	50
2017 Q2	$20.8M	Buy	385,937 +356	+0.1%	+$19K	0.82%	46
2017 Q1	$20.3M	Sell	385,581 -297	-0.1%	-$15.1K	0.83%	45
2016 Q4	$18.6M	Buy	385,878 +17,313	+5%	+$855K	0.81%	44
2016 Q3	$19.9M	Sell	368,565 -218	-0.1%	-$12K	0.91%	41
2016 Q2	$20M	Buy	368,783 +19,720	+6%	+$1.04M	0.93%	39
2016 Q1	$17.7M	Sell	349,063 -6,880	-2%	-$343K	0.88%	40
2015 Q4	$18M	Sell	355,943 -14,192	-4%	-$723K	0.89%	42
2015 Q3	$17.8M	Sell	370,135 -840	-0.2%	-$43.7K	0.88%	42
2015 Q2	$19.3M	Buy	370,975 +44	+0%	+$2.48K	0.86%	43
2015 Q1	$21.4M	Buy	370,931 +788	+0.2%	+$45.2K	0.95%	38
2014 Q4	$19.8M	Sell	370,143 -1,320	-0.4%	-$73.8K	0.88%	38
2014 Q3	$21.3M	Buy	371,463 +412	+0.1%	+$25.3K	0.93%	34
2014 Q2	$24.8M	Buy	371,051 +3,674	+1%	+$249K	1.05%	28
2014 Q1	$24.5M	Sell	367,377 -364	-0.1%	-$24.6K	1.1%	26
2013 Q4	$24.5M	Sell	367,741 -1,048	-0.3%	-$68K	0.88%	29
2013 Q3	$23.1M	Hold	368,789	–	–	0.91%	28
2013 Q2	$23M	Buy	+368,789	New	+$23.4M	0.82%	32

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Klingenstein Fields & Co's GSK Position: Q2 2026 in Review

Klingenstein Fields & Co sold out of GSK (GSK) in Q2 2026, closing a stake of 3,731 shares — an estimated $206K sold.

Klingenstein Fields & Co first reported a position in GSK in Q2 2013 and held it in 41 quarters. The position peaked at $24.8M in Q2 2014. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Klingenstein Fields & Co reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
Klingenstein Fields & Co sold 3,731 GSK shares in Q2 2026, an estimated $206K.
Klingenstein Fields & Co first reported a position in GSK in Q2 2013 and held it in 41 quarters.
Klingenstein Fields & Co's GSK position peaked at $24.8M in Q2 2014.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Klingenstein Fields & Co's 13F filing for Q2 2026, filed 5 Aug 2026.